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ABSTRACT
Increasing antibiotic resistance by human pathogenic bacteria is a global health
concern. This health challenge calls for increased multi-disciplinary research efforts to address
the issue and one such effort is concerned with the development of novel single molecule agents
with more than one bacterial target site for action or interaction. This review covers molecular
design considerations and some possible synthetic molecular entities for potential triple-action
antibacterial agents and related pro-drugs, particularly those based on the quaternary alkaloid
berberine.
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Introduction
A number of recent health reports and papers [1-5] have highlighted the growing
threat of increasing resistance to antibiotics of human pathogenic bacteria, especially some
Gram-negative bacteria. This is a major health care issue worldwide and presents key
multi-disciplinary research challenges. One strategy that has been adopted is the use of drug
combinations. These can include two separate antibacterials with complementary activities [6] or
one antibacterial with a second agent not necessarily antibacterial but which may enhance the
activity of the other by blocking, for example, a resistance mechanism [7-9] or by aiding
antibiotic penetration as in the case of the drug pentamidine which in Gram-negative bacteria
disrupts the outer membrane and allows ingress by antibiotics to then attack the pathogenic
bacteria [10]. More recently this has been extended to combinations of three separate drugs with
some promising results [11-13]. Synergistic interactions have been observed with the combination
of thymol, ethylendiaminetetraacetic acid (EDTA), and vancomycin, including a 16-fold
enhancement in sensitivity of the Gram-negative pathogenic bacterium Escherichia coli (E. coli)
[12]. The phenolic monoterpene thymol has antibacterial properties while the glycopeptide
antibiotic vancomycin affects cell wall synthesis and is used for the treatment of infections
caused by Gram-positive bacteria. EDTA, a chelating agent for Ca2+ and Mg2+ ions, was included
as these ions are important in bacterial cell wall protection (particularly in Gram-negative bacteria)
and it was thought that if this protection was compromised by chelation then other antibacterials
might be more effective [12]. This did in fact seem to be the case. In other recent elegant work,
Yeh and co-workers [11] have shown that the triple drug combination of ciprofloxacin, clindamycin
and streptomycin revealed a lethal emergent antibacterial synergy against E. coli, although other
triple antibiotic combinations did not. They have also developed [14] a very interesting
framework to evaluate potentially therapeutically valuable synergies from three-way interactions
of separate antibacterials using E. coli.
One significant potential problem, though, with drug combination antibacterial
therapies is that in vivo the different drugs are likely to have different pharmacokinetic profiles
which could compromise antibacterial potency with different concentrations of drugs being
present at different times at the bacterial target sites. Also undesirable off-target effects are more
likely to be an issue.
As an alternative to combinations, single compounds whose structures incorporate
different molecular recognition features to enable targeting of a number of biological target sites
can be an attractive option. This design paradigm is, along with multiple drug combinations that
interact with different biological targets, part of the area referred to in general as polypharmacology
[15, 16] (or as a multivalent approach [17]). These single molecules may be hybrids or agents
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which stay intact at each target site, or single pro-drugs which can be cleaved selectively in or
near the bacteria to release separate active components in situ. Work on such multi-action
compounds to date has largely focused on the design, synthesis and microbiological evaluation
of dual action, or potentially dual action, compounds. These have been extensively reviewed
[8,18-21], but some examples include 13-substituted derivatives (1) and (2) of the antibacterial
quaternary alkaloid berberine (3) in which the 13-substituent incorporates structural elements of
the potent NorA bacterial efflux pump inhibitor INF55 (5-nitro-2-phenyl-1H-indole) with
methylene [22-24] or methylene ether [25] linking groups to berberine. Berberine is a substrate
for this pump which severely comprises its antibacterial activity in Staphylococcus aureus for
example. The hybrid salts (1, X = Br) and (2, X = Br) show potent activity against S. aureus.
Interestingly, bifunctional antibiotics have also been found in nature as exemplified
by the antibiotic simocyclinone D8 (4) [26]. This antibiotic, which was isolated from the soil
microorganism Streptomyces antibioticus Tü 6040, is active against Gram-positive bacteria but
not Gram-negatives, and is cytostatic against some human tumour cell lines. It is a very large
molecule composed of a chlorinated aminocoumarin at one end and an angucyclic polyketide at
the other, with a tetraene and deoxyhexose sugar unit linking the two. The molecule inhibits
bacterial DNA gyrase by stopping DNA binding to the enzyme. Crystallographic analysis has
revealed that (4) binds to the E. coli gyrase A subunit via two binding pockets that separately
interact with the polyketide and aminocoumarin structural components [26]. These extra binding
pockets, which each differ from the quinolone antibacterial binding site, may offer some new
avenues for antibacterial drug development.
Less, however, has been done with single molecule triple-action antibacterials
although the potential here for such agents or related pro-drug entities is significant and
multifaceted. Acting at three bacterial target sites synchronously or near synchronously could
result in very potent antibacterial activity and greatly hinder resistance development. In this
article, some general design parameters for potential single molecule triple action antibacterials
are discussed, together with some specific known or suggested molecular expressions of these
agents.
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Simocyclinone D8 (4)
Discussion
Design Parameters
The general design parameters are similar to those involved with antibacterial
dual-acting hybrids [8, 19, 21] and pro-drugs [8], although there are added possibilities when
three separate action modes with respect to the biological targets are considered. In addition
to direct antibacterial targets like interfering with cell wall formation, or bacterial DNA function
or protein synthesis, the indirect activities could include a range of combinations including
dislocation of quorum sensing [27], toxin blockade, impacts on the uptake of essential nutrients,
like iron, or the inhibition or attenuation of bacterial efflux pump activity. Efflux pumps
represent an important, although not the only, resistance mechanism for bacteria to counteract
antibacterials by pumping them out of the cell thus reducing their concentrations to sub-effective
levels [28, 29]. In addition, efflux pumps also have a number of other functions, such as
extrusion of endogenous metabolites like the siderophore, enterobactin, or the efflux of toxic
endogenous metabolic intermediates [28]. So inhibiting efflux pumps could have other
deleterious bacterial effects. Efflux pump inhibitors have been shown to decrease the emergence
of resistance as well as reducing biofilm formation and bacterial virulence [29]. Clearly many
direct and indirect action combinations are possible, but it is essential in the design of such singe
molecule agents to consider possibilities for potentiation or synergism, rather than antagonistic
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interactions or just additive interactions [30]. The evaluation protocols elaborated by Yeh and
co-workers [14] for combinations of three agents will be useful in defining activity groupings in
triple action agent design.
Chemically, the new designed agents need to be stable and be relatively readily
accessible synthetically, with syntheses scalable to enable larger quantities for more extensive
biological testing if required. In addition physicochemical properties like molecular weight, water
solubility, lipophilicity, and numbers of H-bond donors and acceptors need to be considered,
amongst others, for potential oral administration, although intravenous administration is an
alternative if this is not possible. Potentially toxic structural moieties should also be avoided
together with functionality likely to be a problem metabolically. Biologically, the potential
antibacterial activity spectrum, potency (particularly against drug resistant strains), the
assessment of rapid or slow resistance development to the new agents, and possible off target
effects need to be considered.
There are a number of other considerations but the focus in this review is on the basic
chemical design side as explored below.
Molecular Expression of Single Molecule Agents
a. Non-cleavable-Triple Action Agents
Many combinations and permutations are possible within a single molecule with
respect to recognition entities and their bacterial target sites. This results in synthetic challenges
as well as efficacy challenges particularly as binding at one target, for example by molecular
recognition unit A, may be negatively impacted by the presence of B and/or C. The effect of the
other recognition units and linker groups on interaction with each target site, as well as the
effective concentration required at each site, are important aspects to consider
While molecular expressions of triple action designs can be grouped in many different
ways, in this article the non-cleavable designs have been sub-divided into six types (i. to vi.)
involving structural recognition elements generalized for simplicity by the letters A, B, and C.
These elements could involve a range of functional groups embedded in one or more rings or not
in ring systems but attached to them or to acyclic units.
General Non-Cleavable Types
In the general types i to iii outlined below, dashed lines are used to indicate variations
in the nature of the linking groups between the recognition elements as many different linkage
architectures are possible affording a range of opportunities for different relative dispositions of
the three recognition element regions generalized as A, B, and C. The recognition elements
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represent the structural motifs likely to interact with the specific bacterial target sites. These are
general design motifs and in each case other possible variations with different ordering of A, B
and C is assumed. With all these structural types, the design needs to be such as to resist
chemical or enzymatic cleavage so they reach their target biological interaction sites intact.
Type i. A - - B - - C
With this type, two linking groups are involved and these links could include acyclic
(linear or branched) groups with one or more atoms and/or one or more cyclic groups including
spirocyclic ones. Incorporating such rings in the linkers offers the prospect of different
dispositions of the motifs A, B and C and spirocyclic systems are an important part of modern
drug design [31]. With this general type, the whole assemblage or parts thereof could also be
embedded in one or more ring systems, with up to three linking groups (e.g. if A was joined to
C by another linking group) or units present.
The biologically active quaternary alkaloid berberine (3) (shown below as its chloride
salt) provides considerable scope for the design of potential triple action agents of general type i.
It is available relatively cheaply commercially, and possesses a number of sites for chemical
manipulation and introduction of different groups. Reaction opportunities include nucleophilic
addition at C8 and electrophilic substitution at C13 (after conversion to dihydroberberine or
8-substituted dihydroberberines and subsequent re-conversion to the quaternary salt structure in
this case [22, 32-34]) and electrophilic substitution at C12 on berberine itself or derivatives [35].
At each of these positions substituents incorporating different biological target motifs, A, or C
(5), for example, could be incorporated. The heterocyclic skeleton in berberine could act as a
recognition element in itself (shown as B in (5)) for DNA binding [36] or inhibition of assembly
of the protein FtsZ, vital for cell division [37, 38].
Berberine, and substituted berberines, can also be converted in good yield to the
corresponding 9-hydroxyberberine (the alkaloid berberrubine) by simple thermolysis [39] providing
a handle for the introduction of further groups by reaction at the 9-OH site produced.
The 9-hydroxyl group could possibly also be used to direct further nucleophilic attack, for
example by boronic acids via a Petasis type reaction [40], to give 8-substituted derivatives of
type (6) or (7). In the case of (7), the recognition element C could then be incorporated by
standard ùclick chemistryû [41] using an appropriate azide derivative to give (8).
In addition to the above sites for the attachment of substituents, the C2,3-fused
methylenedioxy group in berberine can be selectively ring opened to afford a 2,3-diol
(demethyleneberberine) on reaction with boron tribromide under mild reaction conditions [42]
and these groups in turn could then serve as points of attachment for other groups although
regioselectivity issues may be a problem.
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Type ii. A - - - BC
With this type only one multi-atom linking group is present, with the other two
recognition units being directly attached via a common atom or bond. Using berberine as the
starting point one could envisage, for example, attaching the NorA efflux pump blocking moiety,
the 5-nitro-2-phenyl-1H-indole unit (C), directly to berberine B to which was also attached to
another unit A via some appropriate linker group to give (9).
Type iii. A - - B/C
This design type represents an extension of type ii where B and C are partly merged
or even completely merged. In this latter case if all the atoms overlap then B and C would be
equivalent but able to interact separately in different binding modes to two different biological
targets and different from the target of A. Thus it would still be a triple-action agent. This design
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has been realized molecularly with the antibacterial designated PD-2b (10) [43]. This compound
was designed from a linked combination of a protocatechuic acid unit at one end and a sulfadiazine
unit at the other. From computer›based docking studies, the hybrid compound was shown to
target both DNA gyrase subunit B and topoisomerase IV subunit B (of the Gram-negative
pathogen Pseudomonas aeruginosa) as well as dihydrofolate reductase enzymes and is a
potential antibacterial lead structure for further development.
The novel bacterial topoisomerase inhibitor REDX 06213 (11) can also be considered
under this general structural type [44]. This compound, together with others in this group, has an
isoxazoloquinolone group at one end which interacts with DNA (A), a linking group, and then a
pyrido-oxazinone motif (B/C) at the other end which binds to bacterial gyrase and to topoisomerase
IV enzymes. The compound showed good antibacterial activity against multi-drug resistant
strains of E. coli and Acinebacter baumannii with low potential for the development of resistance.
Extensions of the type iii triple action agent design to berberine-based analogues
might potentially include structures like (12) and (13) with the heterocyclic core represented by
B binding to bacterial DNA and the recognition unit incorporated in the linked group A in each
case interacting with a gyrase or topoisomerase enzyme. The fused 5-nitroindolic unit C could
act to interfere with efflux of the whole quaternary salt by the NorA efflux pump. The proposed
structure (13) involves a greater overlap of the rings in the original berberine, and the four-ring
fused heteroaromatic skeleton (a 7H-indolo[2,3-c]quinoline) is isomeric with those present in the
bioactive indoloquinoline alkaloids [45].
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Type iv. ABC
Characteristic of this design type, and of types v. and vi. below, is the absence of any
extra linking groups. So for type iv, the three recognition elements could each be joined directly
via one or two common atoms and one or two common bonds. As far as can be ascertained, there
are no clear examples of this general type of triple action antibacterial agent in the literature,
but possibilities for the future based on berberine can be envisaged where A and C could be
directly attached to berberine (recognition unit B) perhaps at positions 8 and 12, 8 and 13, or 12
and 13.
Type v. AB/C
This type would have no linking groups but would include partial or complete
structural overlaps of two of the recognition elements, and if the latter then with B equivalent to
C two biological targets could be envisaged as noted for type iii. Direct attachment of A to B/C
in structures (12) or (13) could be possible candidates for compounds of type v.
Type vi. A/B/C
With this final general type, a partial or complete overlap of the recognition elements
could be envisaged, although it is less likely to be complete overlap of all three units to have one
molecule interacting with similar binding strengths at three different biological targets with the
same recognition element. Literature examples here include the diazabicyclooctane derivatives
OP0595 (14) [46, 47], and Zidebactam (15) [48], plus the modified fluoroquinolone derivative
Levonadifloxacin (16) and its oral aminoacid ester prodrug. [49] The core diazabicyclooctanone
unit in (14) and (15) acts like a ß-lactam unit; OP0595 inhibits class A and C ß-lactamases as
well has having good antibacterial activity against a number of Gram-negative bacteria through
strong binding to the penicillin-binding protein PBP2. Furthermore, (14) acts as what is referred
to [46] as an çenhanceré of the antibacterial activity of ß›lactams which bind to other penicillin-
binding proteins, with this effect being independent of the blocking of the ß-lactamases [46].
Zidebactam (15) is also a triple action agent with very good activity against some Gram-negative
bacterial strains [48].
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Levonadifloxacin (16) belongs to the benzoquinolizine fluoroquinolone group and is
a bactericidal agent active against quinolone resistant MRSA (Methicillin-resistant Staphylococcus
aureus). Compound (16) preferentially targets the bacterial enzyme DNA gyrase along with
Topoisomerase IV. In addition, (16) inhibits the NorA efflux pump in S. aureus [49], which is
another resistance mechanism implicated in fluoroquinolones together with resistance developing
through enzyme mutation.
While not described as yet, one could also envisage other compounds of type vi. with
partial structural overlaps and with potentially a triple action profile. For example, part of the
structure (13) could be merged with a unit A as in the structure (17). The merged unit A reflects
part of the flavonoid structure present in the dimeric flavanone, tetrahydroamentoflavone (18)
[50]. Compounds of this type are present in an extract from the Brazilian peppertree, in which
the flavone rich extract showed inhibitory activity against the accessory gene regulator (agr)
alleles in S. aureus without growth inhibition [50]. It thus suppresses quorum sensor expression
and quorum sensing controlled virulence factors. The extract showed very promising activity
in vivo in the treatment of dermonecrosis caused by a virulent strain of MRSA. While the
assessment of pure components does not appear to be reported as yet, compound (18) is a one of
the significant components in the active extract, and it is thus conceivable that compound (17)
could also display quorum quenching activity. With (17) then there would be a DNA focus for
two of the interactions (A/B) while C might interfere with the NorA pump-mediated efflux of the
molecule in S. aureus.
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b. Cleavable›Triple action Pro-drugs.
Similar general structural motifs can be envisaged for the potential triple action
pro-drugs as noted for the triple action agent designs above but with the incorporation of a
cleavable group or groups. However, in order to reduce potential negative off target effects in
vivo, the cleavage reaction should be triggered only when at or in the bacterium. Triggers could
include bacterially specific enzymes like ß›lactamases [51] or peptide deformylase [52], the
latter being involved in the hydrolysis of a terminal N-formyl group from peptides. While
considerable work has been done on inhibitors of this enzyme as antibacterial agents [52] there
is potential for use of this enzyme in the pro-drug context. Other biorthogonal approaches to
pro-drug cleavage [53] involving non-biological, physical or chemical triggers to release the
active component or components from the pro-drug could also be useful if the pro-drug can be
concentrated in bacteria or on their surface.
General Cleavable Types
In these general types, the descriptors A′, B′ , or C′ are used after pro-drug activation
and bond cleavage since other atoms may still be attached at these sites so they would be like A,
B and C and still have the respective key recognition features. In each type below there could be
variations in which linking group is cleaved and the order of A, B, and C.
Cleavable Type i. A - - B - - C  A - - B′ + C′
With this general type of pro-drug design, cleavage of one of the linking groups could
reveal a dual action hybrid ( A - - B′) together with another molecule C′ capable of interacting
with a third separate target involved with the bacterium, the advantage being that the active
components would be released in or near the bacterium. While the initial molecule may have
some or no antibacterial activity in itself, the aim would be to expose active components in high
concentration on reaching the bacterium utilizing bacterially specific enzymes. One possible
molecular expression of this type is illustrated by (19). In this case it is proposed that a
monocyclic-lactam triggering unit, to which C is attached, be linked to a fluoroquinolone core B
also incorporating a further recognition moiety A (Scheme 1). If the ß-lactam in (19) was
cleavable by a ß-lactamase enzyme, then, by analogy with some N-sulfonyloxy-ß-lactam inhibitor
studies [54, 55], a subsequent elimination (1) might ensue to give the fluoroquinolone (ciprofloxacin)
derivative (20) in which the key 3-carboxylic acid would be present. The iminium group
produced in the remaining acyl enzyme moiety (or the ketone hydrolysis product [54]) could
then serve to activate a second elimination (2) to give C′ (21) if the attached fragment C had an
appropriately positioned electron acceptor group. While (20) and (21) could potentially be
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separately prepared and then used in combination, the pro-drug strategy suggested would provide
a means to help overcome any pharmacokinetic issues when used in vivo to treat resistant
bacterial infections. From a synthetic viewpoint, the N-acyloxy substituted ß-lactam unit in (19)
should be accessible based on the carbodiimide and Mitsunobu reaction methodology for other
mono ß-lactams [55].
Scheme 1. Possible fragmentation pathway of the type i pro-drug (19) after ß-lactamase activation.
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Cleavable Type ii. A - - B - - C   A′ + B′ + C′
In this case sequential cleavage of each linking group would lead to the release of
three separate compounds A′, B′ and C′. As an illustrative example, molecule (20) above might
include a feature in the linking group to A which was susceptible to cleavage by a later trigger
to give A′ and perhaps the antibacterial ciprofloxacin as B′.
Cleavable Type iii. A - - B - - C - - X  A - - B - - C′ + X′
With this third design type, selective cleavage of one linking group might result in the
fully active triple action agent being exposed near the biological target sites. In theory, fragment
X′ might also be designed to have a fourth biological action but in this article the focus is on
triple action considerations. By way of example of this type, the cytoplasmic enzyme peptide
deformylase might be considered for cleavage of the C - - X linkage [52]. This enzyme does
appear to have some substrate tolerance and the intermediate or final amine generated in the
formamide hydrolysis process could then serve as a trigger to release a triple action antibacterial
agent in high concentration intracellularly.
Conclusion
There are many possibilities for the design and development of radically new,
triple-action antibacterials and, while the medicinal chemical and other disciplinary challenges
are major, such antibacterial agents could ultimately help to meet the antibiotic resistance threat
and improve health care outcomes in the future.
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